Molecular basis and management of gastrointestinal stromal tumors

Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates v...

Full description

Saved in:

Bibliographic Details
Published in:	World journal of gastroenterology : WJG Vol. 16; no. 22; pp. 2726 - 2734
Main Author:	Bayraktar, Ulas D
Format:	Journal Article
Language:	English
Published:	United States Division of Hematology and Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, 0United States 14-06-2010 The WJG Press and Baishideng
Subjects:	Antineoplastic Agents - therapeutic use Benzamides Drug Resistance, Neoplasm Gastrointestinal Stromal Tumors - drug therapy Gastrointestinal Stromal Tumors - genetics Gastrointestinal Stromal Tumors - pathology Humans Imatinib Mesylate Indoles - therapeutic use Mutation Piperazines - therapeutic use Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-kit - antagonists & inhibitors Proto-Oncogene Proteins c-kit - genetics Pyrimidines - therapeutic use Pyrroles - therapeutic use Sunitinib Topic Highlight Nilotinib Imatinib Sunitinib KIT Gastrointestinal stromal tumor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for firstand secondline treatment of metastatic and unresectable GISTs. In this article, we will r...
Bibliography:	Nilotinib R735 Imatinib Sunitinib 14-1219/R KIT Gastrointestinal stromal tumor; KIT; Imatinib; Sunitinib; Nilotinib Gastrointestinal stromal tumor ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Correspondence to: Ulas D Bayraktar, MD, Division of Hematology and Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave, St 3300, Miami, FL 33136, United States. ubayraktar@med.miami.edu Author contributions: Bayraktar UD, Bayraktar S and Rocha-Lima CM performed the literature search; Bayraktar UD, Bayraktar S wrote the paper; Bayraktar UD, Rocha-Lima CM critically revised the paper. Telephone: +1-305-4580998 Fax: +1-305-5850037
ISSN:	1007-9327 2219-2840
DOI:	10.3748/wjg.v16.i22.2726